Agilent Technologies, Inc.

New York Stock Exchange
Back to all articles
Neutral 0

All News for A : Agilent Technologies - Zacks.com

📊 Agilent Technologies (A) is a Santa Clara-based OEM specializing in test and measurement products across Life Sciences, Diagnostics, and Cross Lab segments.

🏭 The company originated as a spin-off from Hewlett-Packard and primarily uses a direct sales model supplemented by distributors and electronic commerce.

📉 For the quarter ended January 2026, Agilent reported earnings and revenue surprises of -0.52% and -0.27%, respectively, falling short of estimates.

💹 Shares traded lower in pre-market trading following the margin pressure and earnings miss announced on February 24, 2026.

📅 Zacks Equity Research published an analysis on March 27, 2026, evaluating Agilent's stock outlook following the recent 30-day-old earnings report.

📈 Investors are encouraged to use Zacks Earnings ESP tools and evaluate reliance on international revenue for financial stability insights.

🧬 The company serves multiple end markets with a broad portfolio including its LSAG, DGG, and ACG business segments.

⚠️ While top- and bottom-line numbers provide quarterly performance context, analysts recommend examining key metric estimates versus Wall Street expectations.

🔗 Zacks Rank Education and Style Scores resources are available for investors seeking to understand timeliness indicators and trading style fits.

🏆 Agilent currently holds a Zacks Industry Rank within the Medical - Products industry (Bottom 35% of 243 ranked industries).

Bullish Signals
  • Agilent Technologies (A) is an original equipment manufacturer (OEM) with a broad-based portfolio of test and measurement products serving multiple end markets.
  • The company has three distinct business segments: Life Sciences & Applied Markets Group (LSAG), Diagnostics and Genomics Group (DGG), and Agilent Cross Lab Group (ACG).
  • Agilent uses a direct sales model supplemented by distributors, resellers, manufacturers' representatives, telesales, and electronic commerce to distribute its products.
Risk Factors
  • Agilent reported negative earnings surprise of -0.52% and revenue surprise of -0.27% for the quarter ended January 2026, falling below Wall Street estimates.
  • Shares traded lower in pre-market despite revenue beat due to margin pressure and earnings miss, indicating investor concern over profitability.
  • Industry Rank is at the Bottom 35% (159 out of 243) with only a C VGM Style Score, suggesting weaker relative performance compared to peers.
Full Analysis
The provided text appears to be a collection of Zacks.com articles and informational pages rather than a single news article about Agilent Technologies. The content primarily details Zacks' proprietary rating systems, including the short-term and long-term "Zacks Rank," which grades stocks into five categories from A (best) to F (worst). It explains that investors should target companies with a Zacks Rank of #1 or #2 and an 'A' or 'B' style score. The text also describes the "Zacks Industry Rank," which categorizes 265 X Industries based on their average performance, with the top industry placing in the top 1% and the worst in the bottom 1%. Specific information regarding Agilent Technologies (stock symbol A) indicates that the company is a Santa Clara, CA-based manufacturer spun off from Hewlett-Packard. It operates three business segments: Life Sciences & Applied Markets Group (LSAG), Diagnostics and Genomics Group (DGG), and Agilent Cross Lab Group (ACG). The text notes that Agilent uses a direct sales model supplemented by distributors and resellers. Regarding financial performance, an article from February 24, 2026, states that for the quarter ended January 2026, Agilent reported earnings surprises of -0.52% and revenue surprises of -0.27%, resulting in shares dropping in pre-market trading due to margin pressure and a missed earnings target despite positive revenue growth. The text also includes snippets from February 26, 2026, which suggest that while top-and-bottom-line numbers provide a sense of quarterly performance for the quarter ended January 2026, investors should also examine key metrics against Wall Street estimates and year-ago values to understand future prospects. Other entries discuss comparable companies like Bio-Rad (BIO) and ResMed (RMD), providing their specific earnings surprises for the quarter ended December 2025, though these do not constitute a summary of Agilent's overall news but rather context within Zacks' research ecosystem. The date on the primary update indicates this information was last refreshed on March 27, 2026.